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Abstract. Objective: The adult respiratory distress syn- 
drome (ARDS) and neonatal respiratory distress syn- 
drome (RDS) are characterized by high permeability 
pulmonary edema which contains plasma-derived pro- 
teins inhibiting pulmonary surfactant function. Current- 
ly, discussion continues as to what dose of surfactant is
required for treatment of these syndromes. 
Design: The purpose of this study was to investigate he 
amount of exogenous surfactant eeded to overcome the 
inhibitory components in human plasma. Male adult rats 
suffering from respiratory failure due to surfactant deple- 
tion after whole-lung lavage received human plasma 
(4 ml/kg body weight) mixed with surfactant at different 
concentrations, intratracheally. Rats receiving surfactant 
only at different concentrations served as controls. Blood 
gas analysis was performed. 
Measurements and results: It was demonstrated that 
plasma (4ml/kg~273 mg plasma proteins/kg) mixed 
with surfactant at 300 mg/kg was able to increase and 
maintain PaO2 at normal values. Plasma mixed with sur- 
factant at 100 mg/kg, after initial restoration of blood 
gases, showed deterioration f PaO2 values. Plasma mix- 
ed with surfactant at a dose of 50 mg/kg did not improve 
PaO 2 whereas urfactant at 50 mg/kg, without plasma, 
restored blood gases to pre-lavage values. 
Conclusion: It is concluded that approximately 1 mg sur- 
factant phospholipids i required to overcome the in- 
hibitory effect of approximately 1 mg plasma proteins. 
For clinical practice this means that an excess of surfac- 
tant should be given, or repeatedly be substituted ("titrat- 
ed") at low concentrations, until blood gases improve. 
Key words: Animal model - Blood gases - Respiratory 
failure - Exogenous surfactant therapy - Surfactant in- 
hibition - Plasma proteins 
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The adult respiratory distress syndrome (ARDS) and 
neonatal respiratory distress syndrome (RDS) are both 
characterized by respiratory failure and require therapy 
consisting of intubation and mechanical ventilation with 
high oxygen concentrations. RDS is characterized bypri- 
mary surfactant deficiency due to immaturity of the 
lungs, while in ARDS high permeability pulmonary ede- 
ma exists, containing plasma-derived proteins which in- 
hibit pulmonary surfactant function [1-7]. Due to im- 
paired surfactant function, surface tension at the air-liq- 
uid interphase on the alveolar walls is increased, leading 
to an increased pressure gradient across the alveolar-cap- 
illary membrane, favouring further accumulation of pro- 
tein-rich edema fluid into the alveolar space [8]. 
Several clinical trials have reported successful treat- 
ment with intratracheal surfactant instillation in 
prematures suffering from RDS [9-14]. In these studies, 
however, some infants did not respond to a single dose of 
surfactant and some infants had an only transient im- 
provement of lung function [10, 11]. One reason for this 
could be that surfactant function is inhibited by plasma- 
derived proteins present in intra-alveolar edema fluid. 
A few reports on ARDS patients treated with surfac- 
tant have been published. Although the results from these 
studies are not consistent, he best results were seen in 
those patients treated with higher surfactant concentra- 
tions [15-19]. 
Currently, discussion continues as to what dose of 
surfactant should be used in prematures with established 
RDS and what dose should be used for treatment of 
ARDS. To investigate his, a study was performed in an 
animal model of respiratory failure induced by bron- 
choalveolar lavage (BAL). This model has proven useful 
for a variety of experimental purposes including, e.g. test- 
ing of different surfactant preparations and demonstrat- 
ing that exogenous surfactant restores blood gases to nor- 
mal [20-22]. After respiratory failure was established, 
animals received plasma mixed with surfactant at differ- 
ent concentrations. Plasma was used to simulate protein- 
rich edema, an established characteristic of ARDS. In- 
stead of lung mechanics, blood gas measurements were 
measured, since these have proven to be more sensitive to 
therapeutic nterventions in this model [23]. 
Materials and methods 
Materials 
The surfactant used in these xperiments was a freeze-dried natural sur- 
factant isolated from bovine lungs in basically the same manner as pre- 
viously described [24]. It consists of approximately 90o/0 phospholipids, 
1070 hydrophobic proteins (SP-B and SP-C), the remainder being other 
!ipids such as cholesterol, glyceride and free fatty acids. There is no SP- 
A in this surfactant preparation. This surfactant preparation has proven 
to be highly effective in improving as exchange and lung mechanics in
various animal models of respiratory failure of different etiologies 
[25-27] and in newborn babies uffering from respiratory failure due 
to congenital diaphragmatic hernia [28]. 
Pooled citrated plasma was collected from healthy volunteers and 
prepared according to standard techniques. Protein concentration was 
measured using a modified Lowry method [29], with bovine serum al- 
bumin as standard. Protein concentration f the pooled plasma was 
68.3 mg/ml. 
Animal study 
The protocol was approved by the Animal Care and Use Committee of 
the Erasmus University Rotterdam. 
The studies were performed in 45 male adult Sprague-Dawley rats 
(body weight 300-350g). After induction of anesthesia with nitrous 
oxide, oxygen and halothane (65/33/2~ the animals were tracheo- 
tomized and a catheter was inserted into the carotid artery. Anesthesia 
was maintained with pentobarbital sodium (60 mg/kg/h, i.p.) and mus- 
cle relaxation was attained with pancuronium bromide (0.5 mg/kg/h, 
i.m.). The rats were ventilated with a Servo Ventilator 900C (Siemens- 
Elema, Solna, Sweden) at the following ventilator settings: pres- 
sure-controlled ventilation, FIO 2 = 1.0, ventilation frequen- 
cy = 30/min, peak airway pressure (Ppeak)= 14 cmHzO, positive end- 
expiratory pressure (PEEP) = 2 cmH20 and inspiratory/expiratory ra- 
tio = 1 : 2. 
After reaching steady state (PaO 2 > 500 mmHg) respiratory failure 
was induced by BAL as described by Lachmann et at. [20]. In brief: 
lungs were lavaged 6-7 times with warm saline (37~ 30ml/kg) 
to produce a PaO2<80mmHg at Ppeak=26cmH20 and PEEP= 
6 cmH20. These ventilator settings were unchanged throughout the en- 
tire observation period. 
Approximately 5 rain after PaO 2 < 80 mmHg animals were random- 
ly divided into seven groups: after disconnection from the ventilator, 
Groups I, II, and III (n = 6, n = 7 and n = 7, respectively) immediately 
received intratracheally the undiluted plasma (4ml/kg = 273.2mg 
plama proteins/kg) mixed with surfactant at concentrations of 50, 100 
and 300 mg phosphoIipids/kg body weight, respectively; Groups IV, V 
and VI (n = 6, n = 6 and n = 7, respectively) received surfactant sus- 
pended in saline at concentrations of 25, 50 and 100rag phospho- 
lipids/kg body weight, respectively (total amount of surfactant sus- 
pension was ~ ml/kg); Group VII (n = 6) received undiluted plasma 
(4 ml/kg), intratracheaUy. In all groups intratracheal instillation was 
followed by a bolus of air (32 ml/kg), and mechanical ventilation was 
continued. Before intratracheal instillation, surfactant-plasma ixtures 
were incubated for 30 min at 37 ~ 
Blood samples for measurement of PaO 2 and PaCO 2 were taken 
from the carotid artery before BAL and 5 min after the last lavage (di- 
rectly followed by treatment) and at 5, 30, 60, 90, I20, 150 and 180 rain 
post-treatment (ABL 330; Radiometer, Copenhagen, Denmark). The 
animals were then sacrificed with an overdose of intraarterially admin- 
istered pentobarbital sodium. 
Statistical analysis 
All data are expressed as mean +_ standard eviation (SD). Statistical 
analysis of data was performed using repeated measurements Anovas, 
with time as the repeat variable. When differences between and/or with- 
in groups occurred, these differences were further analyzed with a test 
that compensated for multiple comparison (Student-Newman-Keuls 
test). Statistical significance was accepted at p_< 0.05. 
Results 
Figures 1 a and 1 b show PaO2 values for all groups. The 
intergroup differences both before and after lavage are 
not statistically different. After treatment, the PaO z val- 
ues of groups receiving surfactant onIy at 50 and 
100mg/kg (Groups V and VI, respectively) increase to 
pre-lavage values and remain high during the whole ob- 
servation period and the differences between these groups 
are not significant; for this reason PaO2 values of these 
two groups are used for statistical comparison with other 
groups. Surfactant only at 25 mg/kg (Group IV), after 
initial improvement to pre-lavage values, did not stabilize 
PaO2 values over the whole observation period; the dif- 
ference with Groups V/VI was significant after 60 rain. 
PaO 2 values of rats reveiving plasma (4 ml/kg) mixed 
with surfactant at 100 and 300 mg/kg (Groups II and III, 
respectively) also increase to normal values. Immediately 
after treatment there is no significant difference in PaO 2 
values between Groups II and III and Groups V/VI. 
However, PaO2 values of Group II decrease significantly 
60rain after treatment compared to Group III. PaO 2 
values of Group III remain at high levels throughout the 
observation period and are not significantly different 
from Groups V/VI. PaO2 values of rats receiving plasma 
mixed with surfactant at 50 mg/kg (Group I) did not in- 
crease significantly. Rats receiving plasma only (Group 
VII) died within 60 rain. 
Figures 2a and 2b show the PaCO 2 values for all 
groups. The intergroup differences both before and after 
lavage are not statistically different. PaCO 2 values of 
rats receiving surfactant only at 50 or 100 mg/kg do not 
differ significantly, and are used for comparison with 
other groups. PaCO 2 values of Groups I, II and VII dif- 
fer significantly from Groups V/VI. There is no signifi- 
cant difference in PaCO 2 values between Group III and 
Groups V/VI. There are no significant differences in 
PaCO2 values between Groups II and III. 
Discussion 
It has been established that in both ARDS and RDS the 
alveolar-capillary membrane is highly permeable to 
plasma proteins, leaking from the circulation into the al- 
veolar space, resulting in edema formation [2, 30, 31]. 
BAL material of patients uffering from these syndromes 
demonstrates quantitative and qualitative changes in 
phospholipid composition of surfactant, and contains 
high protein concentrations [2,31- 35]. Saline extracts of 
lung minces from infants who died from RDS and from 
adults with ARDS contained less phospholipids and had 
higher minimal surface tension than similar extracts from 
lungs of patients who died from other causes [15, 36]. 
Several clinical studies have been performed treating in- 
fants suffering from RDS with intratracheal surfactant 
instillation [9.14]. The surfactant preparations u ed vat- 
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Fig. la ,  b. PaO 2 values (mmHg; mean_+SD) before (-) and after BAL 
(= grey bar) in different treatment groups: Groups I, II, and III 
receivedplasma (4ml/kg) mixed with surfactant at 50, 100 and 
300 mg/kg, respectively (a); Groups IV, V and VI received surfactant 
only at 25, 50 and 100 mg/kg, respectively and Group VII received plas- 
ma only (4 ml/kg) (b); t = 0 indicates the PaO 2 values 5 min after BAL, 
immediately followed by treatment; 5"= one rat died; PaO2 = arterial 
oxygen tension. 
ied from natural surfactant (e.g. CLSE, Curosurf, Surfac- 
tant TA and human surfactant) o synthetic surfactant 
preparations (ALEC, Exosurf). The doses used in these 
clinical trials varied from low (60mg/kg) to high 
(200 mg/kg). It has been reported that some infants did 
not respond to, or had an only transient improvement af- 
ter a single treatment of low-dose surfactant [10, 11]. It 
has been suggested that in these patients increased perme- 
ability of the alveolar-capillary membrane l ads to accu- 
mulation of plasma proteins in the alveolar space, caus- 
ing inhibition of the surfactant preparation. This hypoth- 
esis could be confirmed in other clinical studies in which 
better clinical outcome was seen in infants treated with ei- 
ther a higher dose of surfactant [1I] or by treatment with 
multiple doses [14]. Only a few patients with ARDS have 
been treated with surfactant. Although the results from 
these studies are not consistent, the best results were seen 
in patients treated with higher surfactant concentrations 
[15 - 191. 
After treatment of RDS and ARDS with a low dose 
of surfactant the reason for lack of response, or only 
transient improvement, is attributed to the alveolar space 
in these patients being filled with protein-rich edema flu- 
id. Clinical and animal studies have established that these 
plasma-derived proteins inhibit surfactant [1-7, 30, 31, 
Time after treatment (min) 
Fig. 2a, b. PaCO 2 values (mmHg; mean_SD) before (.) and after BAL 
( = grey bar) in different reatment groups: for explanation of groups, 
see Fig. 1; PaCO 2 = arterial carbon dioxide tension 
37-41]. Surface tension studies have shown that several 
plasma proteins inhibit surfactant in a dose-dependent 
manner [7, 38, 39, 42-47]. It is also established that 
some surfactant preparations, especially synthetic surfac- 
rants, are more sensitive to the inhibitory effect of plas- 
ma-derived proteins than other preparations [48-50]. 
However, in recent studies it was demonstrated that addi- 
tion of surfactant-associated proteins increases resistance 
of synthetic surfactants o inhibition of plasma proteins 
[51, 52]. In physiological studies using excised lungs it 
was shown that intratracheal instillation of hemoglobin, 
albumin or membrane lipids decreased lung compliance, 
which could be reversed by intratracheal surfactant instil- 
lation [44]. 
The mechanism by which plasma derived proteins 
inhibit surfactant function is not clear. Balis and col- 
leagues [53] have postulated two different types of surfac- 
tant inhibition. They demonstrated that inhibition of sur- 
factant by serum could be reversed by centrifugating the 
surfactant-serum mixture: the sediment revealed normal 
surfactant function. Mixing surfactant with plasma al- 
lowed clot formation to occur; this "coagulative type" of 
inhibition could not be reversed by centrifugation. Seeger 
and colleagues reported that fibrin monomers are potent 
inhibitors of surfactant; inhibition of surfactant could 
partially be reversed by adding plasmin to the fibrin-sur- 
factant mixture [7]. Other investigators have hypothesiz- 
ed that inhibition of surfactant by plasma derived pro- 
teins is due to competition for space at the air-liquid in- 
terphase. Holm and colleagues reported that at high sur- 
factant concentrations the inhibitory effect of high con- 
centrations of plasma proteins or membrane lipids is 
abolished [44, 45]. The reason for this observation is not 
known. Other studies confirm the probable xistence of 
a competition mechanism: after centrifugation f surfac- 
tant-inhibitor mixtures derived from BAL fluid of ani- 
mals treated with surfactant or after centrifugation of
surfactant-protein mixtures, the sediments containing 
surfactant revealed normal surface tension characteristics 
compared with before centrifugation [2, 37, 40, 45, 53]. 
Also, when these BAL fluids or the surfactant-protein 
mixtures were investigated for surface tension properties, 
it could be demonstrated that after a certain number of 
cycles the minimal surface tension decreased from initial- 
ly high levels to low levels [7, 38, 41, 42]. These findings 
probably indicate that, if there is any chemical interaction 
between proteins and surfactant, his interaction is not 
strong. 
If the mechanism of competition between surfactant 
and plasma proteins is correct, then this would be of 
great importance for treatment of ARDS and neonatal 
RDS. Namely, whether the lungs are filled with plasma- 
derived proteins or not, intratracheal instillation of suffi- 
ciently high doses of surfactant should restore lung func- 
tion. Surfactant treatment of animals with enormous 
amounts of pulmonary edema caused by prolonged ex- 
posure of 100~ oxygen or hydrochloric acid (HC1) aspi- 
ration does not seem to have any positive influence on re- 
storing gas exchange at the concentrations u ed [1, 4]. 
Kobayashi and colleagues have demonstrated that surfac- 
tant treatment was only able to restore gas exchange in 
rabbits uffering from respiratory failure after HC1 aspi- 
ration after lungs had been lavaged, this way removing 
proteins from the alveolar space [4]. This strongly sug- 
gests that a more favorable surfactant/inhibitor ratio was 
established after lung lavage followed by surfactant treat- 
ment. In another study, surfactant instillation at very 
high doses (280-350 mg/kg) was able to restore gas ex- 
change in guinea pigs suffering from severe respiratory 
failure due to high permeability pulmonary edema fter 
intravenous instillation of anti-lung serum [54]; thus a 
more favorable surfactant/inhibitor ratio was obtained 
by giving a large amount of surfactant. Recently, 
Kobayashi and colleagues investigated the capability of 
porcine surfactant mixed with edema fluid at several 
ratios to restore lung function in immature rabbit fetuses, 
as measured by tidal volume at preset insufflation pres- 
sures [5]. It was demonstrated that surfactant (25 mg/ml) 
mixed with edema fluid at a protein to lipid ratio (P/L ra- 
tio) of 2.2 was capable of restoring lung function, where- 
as surfactant mixed with edema fluid at P/L ratio of 11.2, 
was not. Surface tension properties of these mixtures 
demonstrated high minimal surface tensions at P /L_  3.4 
and low surface tensions at P /L< 1.8. In the present 
study a P/L ratio of 0.9 (Group III) was capable of restor- 
ing gas exchange over the 3 hour observation period, 
whereas at P/L ratio of 2.7 (Group II) there was only 
transient improvement. At P/L ratio of 5.5 (Group I), no 
improvement was seen. Our results are in concordance 
with the observations reported by Kobayashi and col- 
leagues, although a different animal model looking at 
different parameters and a different surfactant prepara- 
tion were used [5]. The results confirm the hypothesis of 
the competition mechanism between surfactant and pro- 
teins, although it cannot be ruled out that some direct in- 
teraction between surfactant and proteins occurs. 
The lung lavage model, used in the present study, has 
proven useful for a variety of experimental purposes, in- 
cluding e.g. testing of different surfactant preparations 
and demonstrating that exogenous urfactant restores 
blood gases to normal [20-22]. In this model, the con- 
centmtion of the surfactant preparation (which is more 
or less comparable with all other natural surfactant prep- 
arations) needed to restore blood gases over a 3 hour ob- 
servation period was 50 mg/kg (Fig. 1 B). To get the same 
results when surfactant was mixed with human plasma 
(4ml/kg-273 mg plasma proteins/kg), six times as 
much surfactant (300 mg/kg) was necessary to restore 
and stabilize gas exchange (Fig. 1 A). This means that ap- 
proximately 1 mg surfactant phospholipids i  needed to 
overcome the inhibitory effect of 1 mg plasma proteins. 
Surfactant at 100 mg/kg initially restored gas exchange, 
however appeared not to be enough to overcome the addi- 
tional inhibition by plasma proteins leaking into the alve- 
olar space. Because of this, gas exchange deteriorated af- 
ter initial improvement. In these experiments citrated 
plasma was used to obtain full inhibitory capacity, in- 
cluding fibrinogen. However, the inhibitory components 
in diseased lungs probably consist not only of products 
derived from blood but also consist of, for example, spe- 
cific proteases, inflammatory mediators, bacteria, mem- 
branes, etc. Plasma-derived proteins, however, may be the 
most important compounds of high-permeability edema 
fluid and thus, from this point of view, it makes ense to 
"titrate" the amount of surfactant for replacement thera- 
py by mixing it with full plasma. 
Our results favor the competition hypothesis: when 
mixed with plasma, surfactant at 50 mg/kg shows no im- 
provement, at 100 mg/kg there is only transient improve- 
ment, and at 300 mg/kg there is sustained improvement 
of blood gas values. These results imply that for treat- 
ment of ARDS or established RDS a high concentration 
of surfactant is required to overcome the inhibitory effect 
of plasma-derived proteins. If after surfactant instillation 
there is no, or only transient, improvement of blood gas 
values in patients with either ARDS or RDS (fibrotic 
lungs excluded) this does not mean that surfactant treat- 
ment does not work. It only means that the concentration 
of the surfactant preparation used is too low in relation 
to the amount of surfactant inhibitors in the lungs. This 
raises the question of how to exclude the existence of 
fibrotic lungs. In our clinical practice we investigate his 
as follows: we increase the mean airway pressure in 
mechanically ventilated patients and observe blood gases. 
If blood gases improve this would mean that there are still 
recruitable ung parts which could be stabilized by exoge- 
nous surfactant treatment. On the other hand, if blood 
gases remain stable or even deteriorate after increasing 
mean airway pressure due to further mismatch of the ven- 
tilation/perfusion ratio, surfactant instillation may wors- 
en the clinical situation by filling up the remaining areas 
10 
part ic ipat ing in gas exchange, which  is typical  for f ibrot ic  
lungs. Thus,  before  g iv ing surfactant ,  especial ly after a 
long per iod o f  art i f ic ia l  vent i la t ion (2 -3  weeks), one 
shou ld  always examine i f  there is still some lung tissue left 
which  can be recruited by high vent i la t ion pressures. As  
a consequence,  in t reatment  o f  ARDS or  establ ished 
RDS:  i) sur factant  shou ld  be given as ear ly as possible 
and ii) an  excess o f  sur factant  shou ld  be given, or  repeat- 
edly be subst i tuted ( " t i t ra ted")  at low concentrat ions  un-  
til b lood  gases improve. 
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